Press Release
HealthTrackRx Partners with CDC to Launch Rapid PCR Test for H5N1 to Support Early Detection Amid Nationwide Outbreaks
Denton, TX — April 15, 2025 – HealthTrackRx, the nation’s leading provider of next-morning molecular diagnostics, today announced the development of a PCR test for Avian Influenza A (H5N1), created in partnership with the U.S. Centers for Disease Control and Prevention (CDC) as part of national emergency preparedness efforts. The test is designed for rapid deployment should the outbreak escalate.
H5N1 has been garnering significant attention, as the spread of infection continues to rise among poultry and livestock nationwide. In addition, positive cases of bird flu among humans, with reported hospitalizations and one death, have alerted the healthcare sector nationwide. These outbreaks underscore the evolving nature of highly pathogenic H5N1, highlighting its potential to cross species barriers and cause a pandemic. Health experts emphasize that H5N1 testing is crucial for public health as it enables early detection, promotes public health responses, and prevents future pandemics by continued surveillance of the spread of infection.
“This isn’t just about developing a test—it’s about being ready to respond at scale,” said Dr. Jay Reddy, Chief Scientific Officer at HealthTrackRx. “Our national footprint and next-morning result model uniquely positions us to support public health response when timing matters most. We’re working with the CDC to ensure this test is ready to deploy should the need arise.”
Leveraging its pandemic response experience, including being one of the first labs to receive Emergency Use Authorization (EUA) for COVID-19 testing, HealthTrackRx rapidly developed the H5N1 assay and integrated it into its emergency preparedness infrastructure.
“The H5N1 assay reflects our commitment to staying ahead of emerging threats,” said Dr. Vijay Singh, Vice President of R&D. “We have the research capability, the operational capacity, and the established logistics model to help mitigate future outbreaks with speed and precision.”
HealthTrackRx’s partnership with the CDC included ongoing data-sharing, validation support, and integration with the CDC’s surveillance network. HealthTrackRx is committed to supporting public health agencies and healthcare providers in the timely detection of and responses to H5N1 cases. HealthTrackRx continues to support public health agencies and healthcare providers in the early detection of infectious diseases, building on its legacy of preparedness for outbreaks like Mpox, measles, and COVID-19.
About HealthTrackRx
HealthTrackRx is the nation’s premier infectious disease laboratory, delivering next-morning results through its advanced PCR-based testing solutions. Committed to “Getting People Healthier Faster,” HealthTrackRx partners with healthcare providers nationwide to improve patient outcomes, reduce total care costs, and promote better stewardship of antibiotics. Visit https://www.healthtrackrx.com for more information.
Contact:
Lindsay Phillips
Director of Marketing & Communications
972-833-4745
Related Posts
Denton, TX — April 15, 2025 – HealthTrackRx, the nation’s leading provider of next-morning molecular diagnostics, today announced the development of a PCR test for Avian Influenza A (H5N1), created in partnership with the U.S. Centers for Disease Control and Prevention (CDC) as part of national emergency preparedness efforts. The test is designed for rapid deployment should the outbreak escalate.
H5N1 has been garnering significant attention, as the spread of infection continues to rise among poultry and livestock nationwide. In addition, positive cases of bird flu among humans, with reported hospitalizations and one death, have alerted the healthcare sector nationwide. These outbreaks underscore the evolving nature of highly pathogenic H5N1, highlighting its potential to cross species barriers and cause a pandemic. Health experts emphasize that H5N1 testing is crucial for public health as it enables early detection, promotes public health responses, and prevents future pandemics by continued surveillance of the spread of infection.
“This isn’t just about developing a test—it’s about being ready to respond at scale,” said Dr. Jay Reddy, Chief Scientific Officer at HealthTrackRx. “Our national footprint and next-morning result model uniquely positions us to support public health response when timing matters most. We’re working with the CDC to ensure this test is ready to deploy should the need arise.”
Leveraging its pandemic response experience, including being one of the first labs to receive Emergency Use Authorization (EUA) for COVID-19 testing, HealthTrackRx rapidly developed the H5N1 assay and integrated it into its emergency preparedness infrastructure.
“The H5N1 assay reflects our commitment to staying ahead of emerging threats,” said Dr. Vijay Singh, Vice President of R&D. “We have the research capability, the operational capacity, and the established logistics model to help mitigate future outbreaks with speed and precision.”
HealthTrackRx’s partnership with the CDC included ongoing data-sharing, validation support, and integration with the CDC’s surveillance network. HealthTrackRx is committed to supporting public health agencies and healthcare providers in the timely detection of and responses to H5N1 cases. HealthTrackRx continues to support public health agencies and healthcare providers in the early detection of infectious diseases, building on its legacy of preparedness for outbreaks like Mpox, measles, and COVID-19.
About HealthTrackRx
HealthTrackRx is the nation’s premier infectious disease laboratory, delivering next-morning results through its advanced PCR-based testing solutions. Committed to “Getting People Healthier Faster,” HealthTrackRx partners with healthcare providers nationwide to improve patient outcomes, reduce total care costs, and promote better stewardship of antibiotics. Visit https://www.healthtrackrx.com for more information.
Contact:
Lindsay Phillips
Director of Marketing & Communications
972-833-4745